Kenvue stock is down 28% in 2025 amid controversy surrounding its Tylenol brand, which is linked to autism when used during pregnancy.

Starboard Value CEO Jeff Smith said that he is "thrilled to own" Kenvue (NYSE:KVUE) even though the stock is down ~30% year to date. The activist investor joined Kenvue's board in March as part of a proxy fight settlement,

A potential legal headache for consumer healthcare giant Kenvue ( KVUE 8.36%) was causing pain for investors on Thursday. Such troubles tend to spook the market; hence the more than 13% sell-off of Kenvue across that trading session. The S&P 500 ( ^GSPC 0.53%), by comparison, did much better on the day with "only" a 0.6% decrease.

Explore Kenvue Inc. (NYSE:KVUE) trends, dividends, and market activity among consumer stocks in S&P 500 today.

I would like to receive updates and special offers from Dow Jones and affiliates. I can unsubscribe at any time.

(Reuters) -Kenvue has urged U.S. regulators to reject a request seeking autism warning label on its popular over-the-counter pain medication Tylenol for use during pregnancy, after President Donald Trump linked the drug to the condition.

If you’re eyeing Kenvue stock and asking yourself what to do next, you’re definitely not alone. There has been more than a little turbulence lately, and for anyone considering an entry or exit, understanding what’s really driving the recent moves is essential.